Bio­phar­ma ramps up lob­by­ing spend as drug pric­ing leg­is­la­tion nears

The top bio­phar­ma com­pa­nies in the world col­lec­tive­ly spent more than $40 mil­lion in just the first quar­ter of 2021 on lob­by­ing Con­gress as part of prepa­ra­tions to stave off ma­jor drug pric­ing leg­is­la­tion that’s ex­pect­ed lat­er this year.

Al­though the num­bers are not dra­mat­i­cal­ly high­er than what the com­pa­nies col­lec­tive­ly spent in the first quar­ter of 2020, some like Glax­o­SmithK­line, Te­va, Mer­ck and John­son & John­son have al­ready in­creased their quar­ter­ly lob­by­ing spend in 2021 by about $1 mil­lion more each when com­pared to re­cent quar­ters in 2020.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER